Key result
The AGT rs5050 GG-genotype was associated with a shorter median survival compared to TT- and TG-genotypes in patients with astrocytoma.
Why the study?
Does the AGT rs5050 GG-genotype predict worse survival in patients with newly diagnosed primary astrocytoma?
Cohort (n=48)
No
Does the AGT rs5050 GG-genotype predict worse survival in patients with newly diagnosed primary astrocytoma?
The AGT rs5050 GG-genotype is associated with significantly shorter survival in patients with astrocytoma, suggesting its potential as a blood-based prognostic biomarker.
Answers are grounded in this paper and cite their sources.
May support AGT rs5050 as a prognostic biomarker in astrocytoma; leaves open prospective validation before clinical adoption.
INTRODUCTION: Renin-angiotensin system (RAS) in brain cancer represents a scarcely explored field in neuro-oncology. Recently, some pre- and clinical studies have reported that RAS components play a relevant role in the development and behavior of gliomas. The angiotensinogen (AGT) rs5050 genetic variant has been identified as a crucial regulator of the transcription of AGT mRNA, which makes it a logical and promising target of research. The aim of this study was to determine the relationship between the AGT rs5050 genetic variant in blood with prognosis in astrocytoma. METHODS: A prospective pilot study was performed on forty-eight astrocytoma patients, who received the standard-of-care treatment. Blood samples were taken prior to surgery and DNA was sequenced using Ion Torrent next-generation sequencing and analyzed by Ion Reporter software. Descriptive, bivariate, multivariate, and survival analyses were performed using SPSS v21, STATA 12 and GraphPad Prism 7. RESULTS: Median follow-up was 41 months (range 1-48). Survival analysis showed a significant difference between the rs5050 genotypes (p = .05). We found lower survival rates in individuals with the GG-genotype of rs5050 AGT compared to patients with the TT- and TG-genotype (2 months vs. 11.5 months, respectively [p = .01]). In bivariate and multivariate analyses, GG-genotype was negatively associated with survival. CONCLUSIONS: In patients with astrocytoma, AGT rs5050 GG-genotype was associated with poor prognosis. We propose this germline genetic variant as a complementary biomarker, which can be detected practically and safely in blood samples or saliva.
No takes yet. Share an insight, caveat, or question.
Perdomo‐Pantoja et al. (2018) conducted a cohort in Astrocytoma (n=48). AGT rs5050 GG-genotype vs. TT- and TG-genotypes was evaluated on Median survival in months (p=0.01). The AGT rs5050 GG-genotype was associated with a shorter median survival compared to TT- and TG-genotypes in patients with astrocytoma.
Synapse has enriched 10 related papers. Consider them for comparative context: